Amkardia s.r.o.

Research site

Czechia Rovna 423/3, Styrice, 639 00 Brno, Czechia

2 trials recruiting
Arteriosclerosis · Atrial fibrillation · Cardiac failure
Adult patients

About Specializations

Amkardia s.r.o. in Brno, Czechia specialises in clinical trials of conditions such as Arteriosclerosis, Atrial fibrillation, Cardiac failure, Cerebrovascular accident prophylaxis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Amkardia s.r.o. in Brno-Stred, clinical research focuses on cardiovascular diseases, with studies centered on atherosclerotic heart and blood vessel disease and atrial fibrillation. These trials are designed to assess new ways to reduce major heart and vascular complications and improve protection against stroke and systemic embolism.

Evaluating a new approach for people with atherosclerotic cardiovascular disease whose current treatment is not sufficiently effective
Studying whether a treatment can better prevent stroke and systemic embolism in atrial fibrillation
Comparing safety and overall benefit in patients at risk for serious cardiovascular events

The site’s work in cardiology is aimed at improving treatment effectiveness, lowering bleeding and clotting risks, and supporting better long-term outcomes for patients with high-risk heart and vessel conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Rovna 423/3, Styrice639 00 BrnoCzechia

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 6

More sites in Brno Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Obicetrapib
Sponsor:NewAmsterdam Pharma B.V.

Contact Research Centre

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Balcinrenone
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites